神経痛治療薬市場：治療法、適応症、流通チャネル別-2025-2030年の世界予測

神経痛治療薬市場は、2023年に10億6,000万米ドルと評価され、2024年には12億米ドルに達すると予測され、CAGR 12.41％で成長し、2030年には24億2,000万米ドルに達すると予測されています。

神経痛治療薬は、三叉神経痛や帯状疱疹後神経痛などの症状でよく見られる、神経の損傷、炎症、機能障害によって生じる神経疼痛の管理と緩和を指します。神経痛治療薬の必要性は、罹患者の著しい不快感と生活の質の低下に起因しており、効果的な解決策に対する継続的な需要を煽っています。これらの治療法は、抗けいれん薬や抗うつ薬などの医薬品から、神経ブロック、神経調節、さらには外科的介入などの高度な治療法まで多岐にわたる。エンドユーザーは、病院、疼痛管理センター、神経学・神経外科専門のクリニックなどです。市場開拓の原動力となっているのは、神経障害性疼痛疾患の増加、患者の意識の高まり、薬剤開発と医療技術の進歩です。しかし、高額な治療費、長期間の薬物使用に伴う副作用、決定的な治療法の欠如といった課題は、市場拡大の妨げとなる可能性があります。さらに、低所得地域ではヘルスケアへのアクセスが限られているため、治療の普及が制限される可能性があります。好機は、非侵襲的神経調節装置の開発、新規ドラッグデリバリーシステム、個人の遺伝的体質に合わせた個別化医療アプローチなどの革新的分野にあります。企業は、診断や治療戦略を強化するために人工知能や機械学習を探求することもできます。官民パートナーシップを奨励し、効果を最大化しながらコストを最小化するための調査に投資することも、大きな利益をもたらす可能性があります。このような機会があるにもかかわらず、規制上のハードルや臨床試験に時間がかかるという性質が、依然として大きな障壁となっています。競合情勢市場には急速な技術進歩があり、大手企業が市場シェアを争う競争環境があるため、絶え間ない技術革新が求められています。低侵襲治療に対する患者の嗜好や、疼痛管理に対するホリスティックなアプローチなど、新たな動向を継続的にモニタリングすることは、このダイナミックな市場で利益を得ようとする企業にとって極めて重要です。

市場力学：急速に進化する神経痛治療薬市場の主要市場インサイトを公開

神経痛治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢化人口の増加による神経痛の発生率の増加
  • 神経痛治療薬製品に関する認知を広めるための政府の取り組み
• 市場抑制要因
  • 神経痛治療に伴う高コスト
• 市場機会
  • 技術の進歩により、薬剤や手術の必要性がなくなる
  • 新興経済諸国における外科的・薬理学的治療の発展
• 市場の課題
  • 薬による副作用の持続

ポーターの5つの力：神経痛治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：神経痛治療薬市場における外部からの影響の把握

外部マクロ環境要因は、神経痛治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析神経痛治療薬市場における競合情勢の把握

神経痛治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス神経痛治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、神経痛治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨神経痛治療薬市場における成功への道筋を描く

神経痛治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化による神経痛の発生率増加
    • 神経痛治療薬製品に関する認知度を高める政府の取り組み
  • 抑制要因
    • 神経痛の治療にかかる高額な費用
  • 機会
    • 技術の進歩により、薬や手術の必要性がなくなる
    • 新興経済諸国における外科的治療と薬物治療の開発
  • 課題
    • 薬による持続的な副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 神経痛治療薬市場治療別

• 薬物ベース
  • 抗けいれん薬
  • 三環系抗うつ薬
• 手術
  • バルーン圧縮
  • グリセロール注射
  • 微小血管減圧術
  • 高周波熱傷治療
  • 定位放射線手術

第7章 神経痛治療薬市場適応症別

• 糖尿病性神経障害
• 肋間神経痛
• 後頭神経痛
• 末梢神経痛
• 帯状疱疹後神経痛
• 三叉神経痛

第8章 神経痛治療薬市場：流通チャネル別

• ドラッグストア
• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカの神経痛治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の神経痛治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの神経痛治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Biogen Inc.
• Cadila Healthcare
• GLENMARK PHARMS LTD.
• H. Lundbeck A/S
• Janssen Pharmaceuticals, Inc.
• Lupin Limited
• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Teikoku Pharma USA, Inc.
• Teva Pharmaceuticals Ltd.
• Torrent Pharmaceuticals Ltd.
• UCB Group

LIST OF FIGURES

• FIGURE 1. NEURALGIA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. NEURALGIA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. NEURALGIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. NEURALGIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEURALGIA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEURALGIA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANT MEDICINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY BALLOON COMPRESSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GLYCEROL INJECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY MICROVASCULAR DECOMPRESSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RADIOFREQUENCY THERMAL LESIONING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INTERCOSTAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OCCIPITAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PERIPHERAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. CANADA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 48. CANADA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 49. CANADA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 50. CANADA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. CHINA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 75. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 76. CHINA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 77. CHINA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. INDIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 80. INDIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 81. INDIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 82. INDIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. INDIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. ITALY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 166. ITALY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 167. ITALY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 168. ITALY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 169. ITALY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 185. POLAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 186. POLAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 187. POLAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 188. POLAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. POLAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 190. QATAR NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 191. QATAR NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 192. QATAR NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 193. QATAR NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 194. QATAR NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 240. NEURALGIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 241. NEURALGIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Neuralgia Treatment Market was valued at USD 1.06 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 12.41%, to USD 2.42 billion by 2030.

Neuralgia treatment refers to the management and alleviation of nerve pain, which may arise due to damaged, irritated, or dysfunctional nerves often seen in conditions like trigeminal neuralgia and postherpetic neuralgia. The necessity of neuralgia treatment stems from the significant discomfort and reduced quality of life for affected individuals, fueling an ongoing demand for effective solutions. The application of these treatments spans pharmaceuticals, such as anticonvulsants and antidepressants, to advanced therapies like nerve blocks, neuromodulation, and even surgical interventions. End-users comprise hospitals, pain management centers, and specialty clinics dedicated to neurology and neurosurgery. Market growth is being driven by increasing incidences of neuropathic pain conditions, growing patient awareness, and advancements in drug development and medical technologies. However, challenges like high treatment costs, side effects associated with long-term medication use, and a lack of definitive cures can impede market expansion. Furthermore, limited healthcare access in low-income regions can restrict treatment uptake. Opportunities lie in innovative areas like developing non-invasive neuromodulation devices, novel drug delivery systems, and personalized medicine approaches tailored to an individual's genetic makeup. Companies can also explore artificial intelligence and machine learning to enhance diagnosis and treatment strategies. Encouraging public-private partnerships and investing in research to minimize costs while maximizing efficacy can also yield substantial benefits. Despite these opportunities, regulatory hurdles, and the time-consuming nature of clinical trials remain considerable barriers. The neuralgia treatment market is characterized by rapid technological advancements and a competitive landscape where major players vie for market share, prompting constant innovation. Continually monitoring emerging trends, such as patient preferences for minimally invasive treatments and holistic approaches to pain management, will be crucial for businesses aiming to capitalize on this dynamic market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuralgia Treatment Market

The Neuralgia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidences of neuralgia due to the rise in the aging population
  • Government initiatives to spread awareness regarding neuralgia treatment products
• Market Restraints
  • High-cost associated with the treatment of neuralgia
• Market Opportunities
  • Technological advancement eliminates the need for drugs and surgery
  • Developing surgical and pharmacological treatment in developing economies
• Market Challenges
  • Persistent side effects from medications

Porter's Five Forces: A Strategic Tool for Navigating the Neuralgia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuralgia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuralgia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuralgia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuralgia Treatment Market

A detailed market share analysis in the Neuralgia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuralgia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuralgia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuralgia Treatment Market

A strategic analysis of the Neuralgia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuralgia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Biogen Inc., Cadila Healthcare, GLENMARK PHARMS LTD., H. Lundbeck A/S, Janssen Pharmaceuticals, Inc., Lupin Limited, Merz Pharma GmbH & Co. KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teikoku Pharma USA, Inc., Teva Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and UCB Group.

Market Segmentation & Coverage

This research report categorizes the Neuralgia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment, market is studied across Drug-Based and Surgery. The Drug-Based is further studied across Anticonvulsant Medicines and Tricyclic Antidepressants. The Surgery is further studied across Balloon Compression, Glycerol Injection, Microvascular Decompression, Radiofrequency Thermal Lesioning, and Stereotactic Radiosurgery.
• Based on Indication, market is studied across Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, and Trigeminal Neuralgia.
• Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidences of neuralgia due to the rise in the aging population
    • 5.1.1.2. Government initiatives to spread awareness regarding neuralgia treatment products
  • 5.1.2. Restraints
    • 5.1.2.1. High-cost associated with the treatment of neuralgia
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancement eliminates the need for drugs and surgery
    • 5.1.3.2. Developing surgical and pharmacological treatment in developing economies
  • 5.1.4. Challenges
    • 5.1.4.1. Persistent side effects from medications
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Neuralgia Treatment Market, by Treatment

• 6.1. Introduction
• 6.2. Drug-Based
  • 6.2.1. Anticonvulsant Medicines
  • 6.2.2. Tricyclic Antidepressants
• 6.3. Surgery
  • 6.3.1. Balloon Compression
  • 6.3.2. Glycerol Injection
  • 6.3.3. Microvascular Decompression
  • 6.3.4. Radiofrequency Thermal Lesioning
  • 6.3.5. Stereotactic Radiosurgery

7. Neuralgia Treatment Market, by Indication

• 7.1. Introduction
• 7.2. Diabetic Neuropathy
• 7.3. Intercostal Neuralgia
• 7.4. Occipital Neuralgia
• 7.5. Peripheral Neuralgia
• 7.6. Postherpetic Neuralgia
• 7.7. Trigeminal Neuralgia

8. Neuralgia Treatment Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Drug Stores
• 8.3. Hospital Pharmacies
• 8.4. Online Pharmacies
• 8.5. Retail Pharmacies

9. Americas Neuralgia Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Neuralgia Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Neuralgia Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Biogen Inc.
• 3. Cadila Healthcare
• 4. GLENMARK PHARMS LTD.
• 5. H. Lundbeck A/S
• 6. Janssen Pharmaceuticals, Inc.
• 7. Lupin Limited
• 8. Merz Pharma GmbH & Co. KGaA
• 9. Novartis AG
• 10. Pfizer Inc.
• 11. Takeda Pharmaceutical Company Limited
• 12. Teikoku Pharma USA, Inc.
• 13. Teva Pharmaceuticals Ltd.
• 14. Torrent Pharmaceuticals Ltd.
• 15. UCB Group